中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
The triterpenoid sapogenin (2 alpha-OH-Protopanoxadiol) ameliorates metabolic syndrome via the intestinal FXR/GLP-1 axis through gut microbiota remodelling

文献类型：期刊论文

作者Xie, Zhifu1; Jiang, Haowen1; Liu, Wei1,2; Zhang, Xinwen1; Chen, Dakai1; Sun, Shuimei1,2; Zhou, Chendong1; Liu, Jia1; Bao, Sheng3; Wang, Xiachang3
刊名CELL DEATH & DISEASE
出版日期2020-09-17
卷号11期号:9页码:10
ISSN号2041-4889
DOI10.1038/s41419-020-02974-0
通讯作者Hu, Lihong(lhhu@njucm.edu.cn) ; Li, Jingya(jyli@simm.ac.cn)
英文摘要Gypenosides, extracts of Gynostemma yixingense, have been traditionally prescribed to improve metabolic syndrome in Asian folk and local traditional medicine hospitals. However, the mechanism of its action remains unclarified. In this work, our results indicated that chronic administration of 2 alpha -OH-protopanoxadiol (GP2), a metabolite of gypenosides in vivo, protected mice from high-fat diet-induced obesity and improved glucose tolerance by improving intestinal L-cell function. Mechanistically, GP2 treatment inhibited the enzymatic activity of bile salt hydrolase and modulated the proportions of the gut microbiota, which led to an increase in the accumulation of tauro-beta -muricholic acid (T beta MCA) in the intestine. T beta MCA induced GLP-1 production and secretion by reducing the transcriptional activity of nuclear receptor farnesoid X receptor (FXR). Transplantation of GP2-remodelled fecal microbiota into antibiotic-treated mice also increased the intestinal T beta MCA content and improved intestinal L-cell function. These findings demonstrate that GP2 ameliorates metabolic syndrome at least partly through the intestinal FXR/GLP-1 axis via gut microbiota remodelling and also suggest that GP2 may serve as a promising oral therapeutic agent for metabolic syndrome.
WOS关键词GLUCAGON-LIKE PEPTIDE-1 ; BILE-ACID METABOLISM ; FXR ; RECEPTORS ; SECRETION ; GROWTH ; LIVER
资助项目China Postdoctoral Science Foundation[2018M632186] ; National Natural Science Foundation of China[81803596] ; National Natural Science Foundation of China[81673493] ; Specialised Plan for Major New Drug Creation[2018ZX09711002-016] ; Natural science foundation of Jiangsu Higher Education Institutions[17KJA360004] ; Natural science foundation of Jiangsu Higher Education Institutions[18KJA360010] ; Programme for Outstanding Scientific and Technological Innovation Team of Jiangsu Higher Education Institutions ; Priority Academic Programme Development of Jiangsu Higher Education Institutions
WOS研究方向Cell Biology
语种英语
WOS记录号WOS:000574542300006
出版者SPRINGERNATURE
源URL[http://119.78.100.183/handle/2S10ELR8/291317]  
专题中国科学院上海药物研究所
通讯作者Hu, Lihong; Li, Jingya
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100864, Peoples R China
3.Nanjing Univ Chinese Med, Jiangsu Key Lab Funct Subst Chinese Med, Nanjing 210023, Peoples R China
推荐引用方式
GB/T 7714		 Xie, Zhifu,Jiang, Haowen,Liu, Wei,et al. The triterpenoid sapogenin (2 alpha-OH-Protopanoxadiol) ameliorates metabolic syndrome via the intestinal FXR/GLP-1 axis through gut microbiota remodelling[J]. CELL DEATH & DISEASE,2020,11(9):10.
APA Xie, Zhifu.,Jiang, Haowen.,Liu, Wei.,Zhang, Xinwen.,Chen, Dakai.,...&Li, Jingya.(2020).The triterpenoid sapogenin (2 alpha-OH-Protopanoxadiol) ameliorates metabolic syndrome via the intestinal FXR/GLP-1 axis through gut microbiota remodelling.CELL DEATH & DISEASE,11(9),10.
MLA Xie, Zhifu,et al."The triterpenoid sapogenin (2 alpha-OH-Protopanoxadiol) ameliorates metabolic syndrome via the intestinal FXR/GLP-1 axis through gut microbiota remodelling".CELL DEATH & DISEASE 11.9(2020):10.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。